This Phase 2 study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of investigational SARS-CoV-2 mRNA vaccine (CVnCoV) at different dose levels and to evaluate the humoral immune response after 1 and 2 dose administrations of CVnCoV.

674 Adults >60 Years of Age and 18 to 60 Years of Age will participate in this phase 2 trial.